{"entity":{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","aka":["Small cell lung carcinoma","SCLC","Oat cell carcinoma","Small cell carcinoma of the lung"],"tldr":"A fast-growing lung cancer. About a third of cases are confined to one side of the chest and are treated to cure with chemotherapy and radiotherapy together; the rest respond to chemotherapy and relapse quickly. After 30 years without progress, durvalumab consolidation, the T-cell engager tarlatamab and antibody-drug conjugates have each lengthened survival since 2024.","summary":"Small-cell lung cancer is a high-grade neuroendocrine carcinoma, almost always caused by smoking, defined by near-universal loss of TP53 and RB1 and by explosive growth. It presents as extensive-stage disease in two thirds of patients, responds to chemotherapy in most, and relapses in almost all. For three decades the treatment was platinum-etoposide, thoracic radiotherapy for limited-stage disease, prophylactic cranial irradiation, and topotecan at relapse.\n\nThe field moved in three steps. First-line chemo-immunotherapy (IMpower133 2018, CASPIAN 2019, ASTRUM-005 2022) added two to five months of median survival and a small tail of long-term survivors. Consolidation durvalumab after chemoradiotherapy for limited-stage disease (ADRIATIC, approved December 2024) was the first curative-intent advance in 30 years, lifting median survival to nearly five years. In relapsed disease, tarlatamab, the DLL3 T-cell engager, became the first drug to beat chemotherapy on overall survival (DeLLphi-304; full FDA approval November 2025), and lurbinectedin plus atezolizumab became the first approved first-line maintenance regimen (IMforte, October 2025).\n\nWhat is next: maintenance intensification with tarlatamab (DeLLphi-305), the B7-H3 ADC ifinatamab deruxtecan in second line (IDeate-Lung02), alpha-emitting SSTR radioligands (RYZ101), subtype-directed therapy (ASCL1, NEUROD1, POU2F3, inflamed), bispecific and trispecific DLL3 engagers, and the settled question of whether MRI surveillance can replace prophylactic cranial irradiation. Screening remains limited to low-dose CT in smokers, which detects few small-cell cancers early.","asOf":"2026-09-25","wikipedia":"https://en.wikipedia.org/wiki/Small-cell_carcinoma","links":[{"label":"NCI PDQ: small cell lung cancer treatment","url":"https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq"},{"label":"IASLC: tarlatamab first-line maintenance data","url":"https://www.iaslc.org/iaslc-news/press-release/tarlatamab-anti-pd-l1-first-line-maintenance-after-chemo-immunotherapy-es"},{"label":"NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462"},{"label":"NICE NG122: lung cancer, management","url":"https://www.nice.org.uk/guidance/ng122/chapter/Management"},{"label":"NICE NG122: lung cancer, palliative interventions and supportive and palliative care","url":"https://www.nice.org.uk/guidance/ng122/chapter/Palliative-interventions-and-supportive-and-palliative-care"},{"label":"NICE NG122: lung cancer, support from clinical nurse specialists","url":"https://www.nice.org.uk/guidance/ng122/chapter/Support-from-clinical-nurse-specialists"},{"label":"NICE NG122: lung cancer, follow-up and patient perspectives","url":"https://www.nice.org.uk/guidance/ng122/chapter/Follow-up-and-patient-perspectives"},{"label":"Macmillan: small cell lung cancer (SCLC)","url":"https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/small-cell-lung-cancer"},{"label":"Roy Castle Lung Cancer Foundation: advanced lung cancer","url":"https://roycastle.org/learn-about-lung-cancer/advanced-lung-cancer/"},{"label":"Roy Castle Lung Cancer Foundation: living with lung cancer","url":"https://roycastle.org/learn-about-lung-cancer/living-with-cancer/"},{"label":"Macmillan: breathlessness","url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/breathlessness"},{"label":"Macmillan: superior vena cava obstruction (SVCO)","url":"https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction"},{"label":"Cancer Research UK: coping with breathlessness when you have lung cancer","url":"https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping-with-breathlessness"},{"label":"Cancer Research UK: fluid on the lungs (pleural effusion)","url":"https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/fluid-on-lungs-pleural-effusion"},{"label":"Marie Curie: what is palliative care?","url":"https://www.mariecurie.org.uk/information/getting-care/palliative-care"},{"label":"Maggie's: support and information","url":"https://www.maggies.org/support-and-information/"},{"label":"Temel et al., early palliative care for patients with metastatic non-small-cell lung cancer (NEJM 2010)","url":"https://doi.org/10.1056/NEJMoa1000678"}],"tags":["lung"],"related":["nsclc","lung-cancer","lung-lcnec","lung-net","dll3-expression"],"cancers":[],"sections":[],"technologies":["t-cell-engager","adc","checkpoint-inhibitor","targeted-alpha-therapy","nhs-targeted-lung-health-check","cytotoxic-chemotherapy","imrt-igrt","sbrt","prophylactic-cranial-irradiation","mri","palliative-care","palliative-radiotherapy","psycho-oncology","peer-support-groups","oncology-nutrition","pain-management","survivorship-care-plan","multidisciplinary-tumour-board","financial-navigation","cbt-fatigue-distress"],"targets":["dll3","b7h3","pdl1","sstr2","tp53","pd1","bcl2","atr","parp","rb1","notch1"],"drugs":[],"companies":["epicentrx","genprex","amgen","roche-genentech","astrazeneca","daiichi-sankyo","merck","jazz","pharmamar","henlius","bms"],"institutions":["mskcc","md-anderson","dana-farber","gustave-roussy"],"pathways":["p53-cell-cycle","sclc-signalling","apoptosis-bcl2","pd1-checkpoint","lineage-plasticity-neuroendocrine","notch","transcription-addiction"],"terms":["limited-extensive-stage","crs","os","pfs","pci-term","pack-year","smoking-cessation","tnm-9-lung-cancer","ebus-tbna","pancoast-tumour","superior-vena-cava-obstruction","malignant-pleural-effusion","brain-metastases","pleural-effusion","pleurodesis","radiation-pneumonitis","irae","cancer-related-fatigue","anaemia","cachexia","performance-status","curative-intent","neutropenia","febrile-neutropenia","bone-metastases","histologic-transformation","driver-mutation"],"trials":["nct07739758","nct06616532","nct06247605","slotman-pci-es-sclc","takahashi-pci","nct06712316","nct02486718","nct03164616","nct05555732","nct06627647","nct06692738","nct03178552","nct06561386","nct05984277","nct07513376","nct06077760","nct06422143","nct07361497","nct03800134","nct06312137","nct06767514","nct06726265","nct05920356","nct07361510","nct06417814","nct05215340","nct06216301","nct06687369","nct06500026","nct06838273","nct06758401","nct06382129","nct06801834","nct06128837","nct06899126","nct06357533","nct04624204","nct07472517","nct03390686","nct04613596","nct04923906","nct06712355","nct05654454","nct06170788","nct05089734","nct01064466","nct06793215","nct07145333","nct06881784","nct06350097","nct07183189","nct06041776","nct07502300","nct06617416","nct07010263","nct06074588","nct06348199","nct06305754","nct07625644","nct02411448","nct04316364","nct06928389","nct05840016"],"people":[],"bottlenecks":[],"keyPapers":["paper-george-sclc-genomic-profiles-nature-2015","paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","paper-gay-sclc-subtypes-inflamed-cancer-cell-2021","paper-baine-sclc-subtype-immunohistochemistry-jto-2020","paper-lee-clonal-history-small-cell-transformation-jco-2017","paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019"],"journals":["clinical-lung-cancer","lung-cancer-journal","thoracic-cancer","chinese-journal-of-lung-cancer"],"dependsOn":[],"notes":["Living with small-cell lung cancer: This is orientation from public patient pages and guidelines, not advice for your case: your own team's instructions and 24-hour number come first. The timeline is the thing that catches people out. NICE NG122 (1.8.1) asks for an assessment by a thoracic oncologist within 1 week of deciding to recommend treatment, and (1.10.2) for radiotherapy to start during the first or second cycle of chemotherapy in limited-stage disease, so decisions arrive close together and the practical, financial and family arrangements are better made early than left. Written from NICE NG122 and the NHS, Roy Castle Lung Cancer Foundation, Macmillan, Cancer Research UK, Maggie's and Marie Curie patient pages, all read on 25 September 2026.","Molecular layer. One genotype and four states. Whole-genome sequencing of 110 tumours found biallelic inactivation of TP53 and RB1 in nearly all of them, sometimes through complex rearrangement rather than point mutation, so a mutation call reads lower (85.8% and 72.5% in the public deposit) than the biology; the two cases with intact RB1 reached the same end through chromothripsis and cyclin D1 overexpression. NOTCH family inactivation in 25%, oncogenic TP73 rearrangements, and chromatin regulators (KMT2D 18.3%, EP300 10.8%, CREBBP 9.2%) make up most of the rest, with kinase mutations only in rare individual cases (George 2015).","Molecular layer. The heterogeneity is transcriptional. Four subtypes are defined by ASCL1, NEUROD1 and POU2F3 expression or by the absence of all three: in 174 patient samples, 69% were ASCL1-dominant, 17% NEUROD1-dominant, 7% POU2F3-positive and the rest double-negative, with 37% co-expressing ASCL1 and NEUROD1, far more overlap than laboratory models predicted (Rudin 2019, Baine 2020). Expression analysis resolved the fourth class as inflamed rather than YAP1-driven, and that class gained most from adding immunotherapy to chemotherapy; the others carry distinct vulnerabilities to PARP, Aurora kinase and BCL-2 inhibition, and platinum shifts tumours towards the inflamed state, which would make subtype a moving target (Gay 2021).","Molecular layer. Subtype decides whether the surface target is there. ASCL1-dominant and NEUROD1-dominant tumours are neuroendocrine-marker high, TTF-1 high and DLL3 high; POU2F3 and other double-negative tumours are low for all three, so a DLL3-directed medicine addresses roughly the 86% that are neuroendocrine-high rather than the whole disease (Baine 2020).","Molecular layer. Some small-cell lung cancer starts as adenocarcinoma. Transformation under EGFR blockade requires RB1 and TP53 loss, which is present from the earliest adenocarcinoma stage and gives a 43-fold risk (Lee 2017, Offin 2019); after transformation the founder EGFR mutation is retained, platinum and etoposide work, checkpoint inhibitors produced no responses in 17 patients, and median survival is 10.9 months (Marcoux 2019)."],"group":"lung","burden":"Small-cell lung cancer makes up about 15% of lung cancers, roughly 250,000 cases a year worldwide, almost entirely in current or former smokers. Limited-stage disease is treated with curative intent and now with durvalumab consolidation. In ADRIATIC, median survival with durvalumab consolidation after chemoradiotherapy was 55.9 months against 33.4 with placebo; in extensive-stage disease first-line chemo-immunotherapy gives a median of about a year. Both are medians in trial populations, so half of those patients lived longer.","subtypes":["Limited-stage (one hemithorax, ~30%)","Extensive-stage (~70%)","SCLC-A (ASCL1-driven, DLL3-high; ~50%)","SCLC-N (NEUROD1)","SCLC-P (POU2F3, tuft-cell-like)","SCLC-I (inflamed, IO-responsive)","Transformed SCLC (from EGFR-mutant NSCLC under TKI)","Combined small-cell / non-small-cell histology"],"biomarkers":["DLL3 (not required for tarlatamab)","B7-H3","SCLC-A/N/P/I subtypes (research)","Stage (limited vs extensive) is the dominant decision","B7-H3 (I-DXd trials)","SSTR2 (RYZ101)","Transcription-factor subtype (ASCL1/NEUROD1/POU2F3/YAP1, research)","PD-L1 and TMB (not predictive in SCLC)","SLFN11 (chemotherapy/PARP sensitivity, research)","ctDNA (research)"],"standardOfCare":[{"setting":"Screening and diagnosis","approach":"Low-dose CT screening in heavy smokers finds some SCLC but stage shift is limited; diagnosis by bronchoscopic or CT-guided biopsy; staging with PET/CT and brain MRI.","refs":["ct","pet-ct","mri"],"guideline":{"nccn":"SCLC guideline, staging workup","version":"NCCN SCLC v2.2026"}},{"setting":"Very limited stage (T1-2 N0, ~5%)","approach":"Lobectomy with mediastinal node dissection or SBRT, followed by adjuvant platinum-etoposide; PCI or MRI surveillance.","refs":["sbrt","platinum-etoposide","prophylactic-cranial-irradiation"],"guideline":{"nccn":"2A"}},{"setting":"Limited stage","approach":"Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance.","refs":["platinum-etoposide","imrt-igrt","durvalumab","adriatic","convert","prophylactic-cranial-irradiation"],"guideline":{"nccn":"1 (durvalumab consolidation, category 1)","esmoMcbs":"A","version":"NCCN SCLC v2.2026"}},{"setting":"Extensive stage, first line","approach":"Carboplatin-etoposide plus atezolizumab or durvalumab (4 cycles), then maintenance immunotherapy; lurbinectedin added to atezolizumab maintenance since 2025 (IMforte). Serplulimab-chemotherapy where approved. Consolidative thoracic radiotherapy for residual thoracic disease in good responders.","refs":["platinum-etoposide","atezolizumab","durvalumab","lurbinectedin","impower133","caspian","imforte","serplulimab"],"guideline":{"nccn":"1 (chemo-IO); 2A (lurbinectedin maintenance)","esmoMcbs":"3"}},{"setting":"Relapsed, platinum-sensitive (≥90 days)","approach":"Tarlatamab (preferred, OS benefit); platinum-etoposide rechallenge; lurbinectedin; topotecan.","refs":["tarlatamab","dellphi-304","lurbinectedin","topotecan"],"guideline":{"nccn":"1 (tarlatamab)","esmoMcbs":"4"}},{"setting":"Relapsed, platinum-resistant (<90 days)","approach":"Tarlatamab; lurbinectedin; topotecan; clinical trials (I-DXd, RYZ101, DLL3 bispecifics).","refs":["tarlatamab","lurbinectedin","topotecan","ifinatamab-deruxtecan","ideate-lung02","ryz101"],"guideline":{"nccn":"1 (tarlatamab)"}},{"setting":"Brain metastases","approach":"Whole-brain radiotherapy or, increasingly, stereotactic radiosurgery for limited numbers of lesions; PCI decisions individualised.","refs":["sbrt","prophylactic-cranial-irradiation","mri"]},{"setting":"Transformed SCLC (from EGFR-mutant NSCLC)","approach":"Platinum-etoposide, often with continued EGFR TKI; immunotherapy benefit uncertain; trials.","refs":["platinum-etoposide","osimertinib"]},{"setting":"Small-cell lung cancer: why the timeline is faster, and what that means for your decisions","approach":"Small-cell lung cancer moves faster than non-small-cell lung cancer, in both directions: it grows quickly and it shrinks quickly with treatment. NICE NG122 builds that into the standard. It says (1.8.1) to arrange for people with small-cell lung cancer to have an assessment by a thoracic oncologist within 1 week of deciding to recommend treatment, which is a far shorter interval than anything in the non-small-cell pathway, and (1.10.2) to start radiotherapy during the first or second cycle of chemotherapy for limited-stage disease rather than after the chemotherapy is finished. What that means for you is that the decisions arrive close together and the waiting-for-results pattern that suits advanced non-small-cell disease does not apply here. The treatment divides at limited against extensive stage. Limited stage: 4 to 6 cycles of cisplatin-based combination chemotherapy, with carboplatin substituted where kidney function, performance status or other illnesses make that safer (1.10.1); twice-daily radiotherapy given with the chemotherapy for people with a performance status of 0 or 1 whose disease fits in a radical radiotherapy volume, or once daily if they decline or cannot manage twice (1.10.2 and 1.10.3); sequential radiotherapy for people who are not well enough for concurrent treatment but respond to chemotherapy (1.10.4); preventive radiotherapy to the brain at 25 Gy in 10 fractions for performance status 0 to 2 where the disease has not progressed (1.10.5); and durvalumab afterwards where the disease has not progressed after chemoradiotherapy (1.10.6). Extensive stage: platinum-based combination chemotherapy if you are fit enough, to a maximum of 6 cycles depending on response and toxicity (1.11.1 and 1.11.2), with durvalumab or atezolizumab added (1.11.3), and thoracic radiotherapy with preventive brain radiotherapy considered for people who responded (1.11.4 and 1.11.5). NICE is unusually frank about the cost of preventive brain radiotherapy, saying it can adversely affect quality of life and that the survival benefits are limited, and has an open research question about replacing it with regular MRI scans. At relapse it says to offer assessment by a thoracic oncologist (1.12.1), to tell people whose disease did not respond to first-line treatment that there is very limited evidence that second-line chemotherapy will benefit them (1.12.2), to offer an anthracycline-containing or a further platinum-based regimen to a maximum of 6 cycles where chemotherapy is suitable (1.12.3), and to offer radiotherapy for palliation of local symptoms (1.12.5). Because the decisions arrive close together, three things are worth doing in the first weeks rather than later: the palliative care referral alongside treatment, for symptom control and not instead of it; the conversation with your team about what matters to you; and the practical paperwork Roy Castle's getting organised material covers.","refs":["cisplatin","carboplatin","etoposide","durvalumab","atezolizumab","adriatic","caspian","impower133","palliative-care","performance-status"],"guideline":{"version":"NICE NG122 (2019, updated March 2024)","url":"https://www.nice.org.uk/guidance/ng122/chapter/Management"}}],"stateOfArt":["Tarlatamab: first OS improvement in relapsed SCLC in decades.","Immunotherapy consolidation in limited stage.","Limited-stage: chemoradiation followed by durvalumab consolidation (ADRIATIC), median OS approaching five years.","Extensive-stage first line: chemo-immunotherapy, now with lurbinectedin-atezolizumab maintenance (IMforte, 2025).","Relapse: tarlatamab (DLL3×CD3) improved OS over chemotherapy (DeLLphi-304) and received full approval in November 2025.","B7-H3 ADC ifinatamab deruxtecan and alpha-emitting SSTR radioligand RYZ101 are in phase 3.","MRI surveillance is displacing prophylactic cranial irradiation while the definitive trial (SWOG S1827) reads out.","Molecular subtypes (A/N/P/I) explain heterogeneity and are moving toward prospective use."],"history":[{"year":1973,"title":"VA Lung Study Group defines limited vs extensive stage","refs":["limited-extensive-stage"]},{"year":1985,"title":"Platinum-etoposide becomes the standard regimen","refs":["platinum-etoposide"]},{"year":1992,"title":"Meta-analysis: thoracic radiotherapy improves survival in limited-stage disease","refs":["imrt-igrt"]},{"year":1996,"title":"Topotecan approved for relapsed disease","refs":["topotecan"]},{"year":1999,"title":"Prophylactic cranial irradiation improves survival in complete responders","refs":["prophylactic-cranial-irradiation"]},{"year":1999,"title":"Twice-daily 45 Gy (Turrisi) sets the limited-stage radiotherapy standard","refs":["imrt-igrt"]},{"year":2017,"title":"CONVERT: once-daily 66 Gy not superior to twice-daily 45 Gy","refs":["convert"]},{"year":2017,"title":"Japanese trial: PCI gives no survival benefit in extensive-stage disease with MRI surveillance","refs":["prophylactic-cranial-irradiation"]},{"year":2018,"title":"IMpower133: first survival gain in decades with atezolizumab","refs":["impower133","atezolizumab"]},{"year":2019,"title":"Rovalpituzumab tesirine (first DLL3 ADC) fails","refs":["dll3"]},{"year":2019,"title":"CASPIAN confirms chemo-immunotherapy with durvalumab","refs":["caspian","durvalumab"]},{"year":2020,"title":"Lurbinectedin accelerated approval in relapsed SCLC","refs":["lurbinectedin"]},{"year":2021,"title":"SCLC molecular subtypes (A, N, P, I) proposed","refs":["idea-sclc-subtype-directed"]},{"year":2024,"title":"Tarlatamab accelerated approval; ADRIATIC changes limited-stage care","refs":["tarlatamab","adriatic"]},{"year":2025,"title":"DeLLphi-304 OS benefit and full approval of tarlatamab; IMforte maintenance approved","refs":["dellphi-304","imforte","lurbinectedin"]},{"year":2026,"title":"Phase 3 readouts pending for I-DXd and tarlatamab maintenance","refs":["ideate-lung02","dellphi-305"]}],"pipeline":["ifinatamab-deruxtecan","ryz101","tarlatamab","pf-08634404","yl201","pm8002","in10018","ak117","al8326","tng260","au-007","or502","dellphi-305","ideate-lung02","serplulimab","lurbinectedin","idea-sclc-subtype-directed","idea-mri-surveillance-replaces-pci","prophylactic-cranial-irradiation","tarlatamab-vs-idxd-sequence","chemo-io-then-maintenance-sclc","t-cell-engager","targeted-alpha-therapy"],"openProblems":["Extensive-stage disease almost always relapses after first-line therapy, so maintenance (lurbinectedin-atezolizumab, tarlatamab) is the current lever; median survival is still barely over a year.","No validated predictive biomarker for immunotherapy benefit; PD-L1 and TMB do not work in SCLC.","Sequencing of tarlatamab, I-DXd, lurbinectedin, and platinum rechallenge is untested.","Cytokine release syndrome and neurotoxicity of T-cell engagers require inpatient step-up dosing that many community centres cannot provide.","Prophylactic cranial irradiation versus MRI surveillance remains unresolved until SWOG S1827 reads out.","Transformed SCLC arising from EGFR-mutant NSCLC has no dedicated evidence base.","Screening rarely catches SCLC early; prevention is tobacco control.","Trials rarely enrol patients with poor performance status, who are common in this disease."],"parent":"lung-cancer"},"route":"/cancers/sclc/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"lung-lcnec","kind":"cancer","name":"Large cell neuroendocrine carcinoma of the lung","route":"/cancers/lung-lcnec/"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/"}],"biomarker":[{"id":"b7-h3-expression","kind":"biomarker","name":"B7-H3 (CD276) expression","route":"/biomarkers/b7-h3-expression/"},{"id":"dll3-expression","kind":"biomarker","name":"DLL3 expression","route":"/biomarkers/dll3-expression/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"rejuv-rehab-respiratory","kind":"technology","name":"Breathing and exercise capacity after lung resection","route":"/technologies/rejuv-rehab-respiratory/"},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/"},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/"},{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/"},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/"},{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"},{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"},{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/"},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"},{"id":"ugt1a1-genotyping","kind":"technology","name":"UGT1A1 genotyping before irinotecan","route":"/technologies/ugt1a1-genotyping/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"target":[{"id":"araf","kind":"target","name":"ARAF","route":"/targets/araf/"},{"id":"arhgef10","kind":"target","name":"ARHGEF10","route":"/targets/arhgef10/"},{"id":"arnt","kind":"target","name":"ARNT","route":"/targets/arnt/"},{"id":"ascl1","kind":"target","name":"ASCL1","route":"/targets/ascl1/"},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/"},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"},{"id":"baz1a","kind":"target","name":"BAZ1A","route":"/targets/baz1a/"},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"btla","kind":"target","name":"BTLA","route":"/targets/btla/"},{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/"},{"id":"chek1","kind":"target","name":"CHEK1","route":"/targets/chek1/"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"},{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/"},{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/"},{"id":"lifr","kind":"target","name":"LIFR","route":"/targets/lifr/"},{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/"},{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/"},{"id":"rictor","kind":"target","name":"RICTOR","route":"/targets/rictor/"},{"id":"slfn11","kind":"target","name":"SLFN11","route":"/targets/slfn11/"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"},{"id":"top2b","kind":"target","name":"TOP2B","route":"/targets/top2b/"},{"id":"top1","kind":"target","name":"Topoisomerase I (TOP1)","route":"/targets/top1/"},{"id":"top2a","kind":"target","name":"Topoisomerase II alpha (TOP2A)","route":"/targets/top2a/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"},{"id":"yap1","kind":"target","name":"YAP1","route":"/targets/yap1/"},{"id":"yes1","kind":"target","name":"YES1","route":"/targets/yes1/"},{"id":"zeb1","kind":"target","name":"ZEB1","route":"/targets/zeb1/"}],"company":[{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/"},{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/"},{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","route":"/companies/alaunos/"},{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"},{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"circle-pharma","kind":"company","name":"Circle Pharma","route":"/companies/circle-pharma/"},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/"},{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/"},{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/"},{"id":"g1-therapeutics","kind":"company","name":"G1 Therapeutics","route":"/companies/g1-therapeutics/"},{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/"},{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/"},{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","route":"/companies/gv20-therapeutics/"},{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/"},{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/"},{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/"},{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/"},{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/"},{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/"},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"},{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","route":"/companies/salubris-biotherapeutics/"},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"},{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","route":"/companies/wayshine-biopharm/"},{"id":"wjog","kind":"company","name":"West Japan Oncology Group","route":"/companies/wjog/"}],"institution":[{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/"},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/"},{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","route":"/institutions/jilin-cancer-hospital/"},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"},{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/"},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/"},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/"},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/"},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/"}],"pathway":[{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/"},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/"},{"id":"notch","kind":"pathway","name":"Notch signalling","route":"/pathways/notch/"},{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/"},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"},{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/"},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/"},{"id":"cell-cycle-engine-cdks","kind":"pathway","name":"The cell-cycle engine (cyclins & CDKs)","route":"/pathways/cell-cycle-engine-cdks/"},{"id":"transcription-addiction","kind":"pathway","name":"Transcriptional machinery & addiction","route":"/pathways/transcription-addiction/"}],"term":[{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/"},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/"},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/"},{"id":"consolidation-therapy","kind":"term","name":"Consolidation therapy","route":"/terms/consolidation-therapy/"},{"id":"curative-intent","kind":"term","name":"Curative intent vs palliative intent","route":"/terms/curative-intent/"},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"},{"id":"differentiation","kind":"term","name":"Differentiation","route":"/terms/differentiation/"},{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/"},{"id":"ebus-tbna","kind":"term","name":"Endobronchial ultrasound (EBUS-TBNA)","route":"/terms/ebus-tbna/"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"haemoptysis","kind":"term","name":"Haemoptysis (coughing up blood)","route":"/terms/haemoptysis/"},{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/"},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/"},{"id":"limited-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (small-cell lung cancer)","route":"/terms/limited-extensive-stage/"},{"id":"lung-uk-drug-access","kind":"term","name":"Lung cancer drugs in England: what NICE has recommended","route":"/terms/lung-uk-drug-access/"},{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/"},{"id":"malignant-pleural-effusion","kind":"term","name":"Malignant pleural effusion","route":"/terms/malignant-pleural-effusion/"},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/"},{"id":"mediastinal-lymph-node-stations","kind":"term","name":"Mediastinal lymph node stations","route":"/terms/mediastinal-lymph-node-stations/"},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/"},{"id":"pack-year","kind":"term","name":"Pack-year","route":"/terms/pack-year/"},{"id":"lung-palliation-breathlessness-effusion-obstruction","kind":"term","name":"Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain","route":"/terms/lung-palliation-breathlessness-effusion-obstruction/"},{"id":"pancoast-tumour","kind":"term","name":"Pancoast (superior sulcus) tumour","route":"/terms/pancoast-tumour/"},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/"},{"id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/"},{"id":"pleurodesis","kind":"term","name":"Pleurodesis and indwelling pleural catheter","route":"/terms/pleurodesis/"},{"id":"pneumonitis","kind":"term","name":"Pneumonitis","route":"/terms/pneumonitis/"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"},{"id":"pci-term","kind":"term","name":"Prophylactic cranial irradiation (PCI)","route":"/terms/pci-term/"},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/"},{"id":"radon","kind":"term","name":"Radon","route":"/terms/radon/"},{"id":"resectability-lung-cancer","kind":"term","name":"Resectability in lung cancer","route":"/terms/resectability-lung-cancer/"},{"id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/"},{"id":"smoking-cessation","kind":"term","name":"Stopping smoking","route":"/terms/smoking-cessation/"},{"id":"superior-vena-cava-obstruction","kind":"term","name":"Superior vena cava obstruction","route":"/terms/superior-vena-cava-obstruction/"},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/"},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/"},{"id":"rejuv-second-topoisomerase-inhibitors-short-latency","kind":"term","name":"Topoisomerase II inhibitors and the shorter latency","route":"/terms/rejuv-second-topoisomerase-inhibitors-short-latency/"}],"trial":[{"id":"nct07563738","kind":"trial","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","route":"/trials/nct07563738/"},{"id":"nct05086692","kind":"trial","name":"A Beta-only IL-2 ImmunoTherapY Study","route":"/trials/nct05086692/"},{"id":"nct07414927","kind":"trial","name":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following E","route":"/trials/nct07414927/"},{"id":"nct07227597","kind":"trial","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","route":"/trials/nct07227597/"},{"id":"nct06698042","kind":"trial","name":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","route":"/trials/nct06698042/"},{"id":"nct05913089","kind":"trial","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","route":"/trials/nct05913089/"},{"id":"nct07513376","kind":"trial","name":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ","route":"/trials/nct07513376/"},{"id":"nct06496490","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","route":"/trials/nct06496490/"},{"id":"nct07111520","kind":"trial","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","route":"/trials/nct07111520/"},{"id":"nct05989542","kind":"trial","name":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","route":"/trials/nct05989542/"},{"id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/"},{"id":"nct06627647","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","route":"/trials/nct06627647/"},{"id":"nct06692738","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","route":"/trials/nct06692738/"},{"id":"nct05984277","kind":"trial","name":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung","route":"/trials/nct05984277/"},{"id":"nct05120349","kind":"trial","name":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","route":"/trials/nct05120349/"},{"id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","route":"/trials/nct06956690/"},{"id":"nct06427941","kind":"trial","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","route":"/trials/nct06427941/"},{"id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","route":"/trials/nct07491497/"},{"id":"nct07020221","kind":"trial","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","route":"/trials/nct07020221/"},{"id":"nct04036682","kind":"trial","name":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","route":"/trials/nct04036682/"},{"id":"nct05199272","kind":"trial","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","route":"/trials/nct05199272/"},{"id":"nct05585320","kind":"trial","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct05585320/"},{"id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/"},{"id":"nct07164170","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","route":"/trials/nct07164170/"},{"id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/"},{"id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct07659782/"},{"id":"nct06695845","kind":"trial","name":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","route":"/trials/nct06695845/"},{"id":"nct06745323","kind":"trial","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","route":"/trials/nct06745323/"},{"id":"nct07182682","kind":"trial","name":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins","route":"/trials/nct07182682/"},{"id":"nct05566041","kind":"trial","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","route":"/trials/nct05566041/"},{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/"},{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/"},{"id":"nct06848699","kind":"trial","name":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06848699/"},{"id":"nct05910827","kind":"trial","name":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","route":"/trials/nct05910827/"},{"id":"nct07253142","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","route":"/trials/nct07253142/"},{"id":"nct06295432","kind":"trial","name":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","route":"/trials/nct06295432/"},{"id":"nct07669779","kind":"trial","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07669779/"},{"id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/"},{"id":"nct06962865","kind":"trial","name":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv","route":"/trials/nct06962865/"},{"id":"nct07269782","kind":"trial","name":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","route":"/trials/nct07269782/"},{"id":"nct06564324","kind":"trial","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","route":"/trials/nct06564324/"},{"id":"nct05870319","kind":"trial","name":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","route":"/trials/nct05870319/"},{"id":"nct04951635","kind":"trial","name":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","route":"/trials/nct04951635/"},{"id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/"},{"id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","route":"/trials/nct06247605/"},{"id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06996782/"},{"id":"nct05654454","kind":"trial","name":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","route":"/trials/nct05654454/"},{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","route":"/trials/nct05246514/"},{"id":"nct07728955","kind":"trial","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","route":"/trials/nct07728955/"},{"id":"nct06812260","kind":"trial","name":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","route":"/trials/nct06812260/"},{"id":"nct07502300","kind":"trial","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","route":"/trials/nct07502300/"},{"id":"nct07640789","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s","route":"/trials/nct07640789/"},{"id":"nct06382129","kind":"trial","name":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU","route":"/trials/nct06382129/"},{"id":"nct06382116","kind":"trial","name":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","route":"/trials/nct06382116/"},{"id":"nct06500026","kind":"trial","name":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","route":"/trials/nct06500026/"},{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/"},{"id":"nct07005128","kind":"trial","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","route":"/trials/nct07005128/"},{"id":"nct05920356","kind":"trial","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","route":"/trials/nct05920356/"},{"id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/"},{"id":"nct06793215","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","route":"/trials/nct06793215/"},{"id":"nct05170204","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","route":"/trials/nct05170204/"},{"id":"nct05789082","kind":"trial","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","route":"/trials/nct05789082/"},{"id":"nct04471727","kind":"trial","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","route":"/trials/nct04471727/"},{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/"},{"id":"nct05592626","kind":"trial","name":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","route":"/trials/nct05592626/"},{"id":"nct02152631","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","route":"/trials/nct02152631/"},{"id":"nct06617416","kind":"trial","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","route":"/trials/nct06617416/"},{"id":"nct07010263","kind":"trial","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","route":"/trials/nct07010263/"},{"id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07623356/"},{"id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct07465757/"},{"id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06095505/"},{"id":"nct05047250","kind":"trial","name":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05047250/"},{"id":"nct06706076","kind":"trial","name":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","route":"/trials/nct06706076/"},{"id":"nct05880706","kind":"trial","name":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ","route":"/trials/nct05880706/"},{"id":"nct07642024","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU","route":"/trials/nct07642024/"},{"id":"nct06498986","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06498986/"},{"id":"nct06838273","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas","route":"/trials/nct06838273/"},{"id":"nct05924841","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct05924841/"},{"id":"nct06437509","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct06437509/"},{"id":"nct06475300","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ","route":"/trials/nct06475300/"},{"id":"nct07264816","kind":"trial","name":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS","route":"/trials/nct07264816/"},{"id":"nct06114511","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","route":"/trials/nct06114511/"},{"id":"nct07178795","kind":"trial","name":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","route":"/trials/nct07178795/"},{"id":"nct07654400","kind":"trial","name":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07654400/"},{"id":"nct04895709","kind":"trial","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct04895709/"},{"id":"nct06465329","kind":"trial","name":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce","route":"/trials/nct06465329/"},{"id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06873555/"},{"id":"nct04440735","kind":"trial","name":"A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors","route":"/trials/nct04440735/"},{"id":"nct07559929","kind":"trial","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","route":"/trials/nct07559929/"},{"id":"nct05668988","kind":"trial","name":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","route":"/trials/nct05668988/"},{"id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/"},{"id":"nct07099898","kind":"trial","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","route":"/trials/nct07099898/"},{"id":"nct06362252","kind":"trial","name":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-","route":"/trials/nct06362252/"},{"id":"nct06281678","kind":"trial","name":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","route":"/trials/nct06281678/"},{"id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/"},{"id":"nct06077760","kind":"trial","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","route":"/trials/nct06077760/"},{"id":"nct07221474","kind":"trial","name":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","route":"/trials/nct07221474/"},{"id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/"},{"id":"nct05276726","kind":"trial","name":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","route":"/trials/nct05276726/"},{"id":"nct05388669","kind":"trial","name":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)","route":"/trials/nct05388669/"},{"id":"nct05297890","kind":"trial","name":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","route":"/trials/nct05297890/"},{"id":"nct07459634","kind":"trial","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","route":"/trials/nct07459634/"},{"id":"nct04302025","kind":"trial","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04302025/"},{"id":"nct05128487","kind":"trial","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","route":"/trials/nct05128487/"},{"id":"nct03800134","kind":"trial","name":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","route":"/trials/nct03800134/"},{"id":"nct07098338","kind":"trial","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07098338/"},{"id":"nct06090266","kind":"trial","name":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","route":"/trials/nct06090266/"},{"id":"nct04351555","kind":"trial","name":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S","route":"/trials/nct04351555/"},{"id":"nct06099782","kind":"trial","name":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol","route":"/trials/nct06099782/"},{"id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","route":"/trials/nct05652686/"},{"id":"nct06731907","kind":"trial","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","route":"/trials/nct06731907/"},{"id":"nct05844150","kind":"trial","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","route":"/trials/nct05844150/"},{"id":"nct05879068","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","route":"/trials/nct05879068/"},{"id":"nct06789796","kind":"trial","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","route":"/trials/nct06789796/"},{"id":"nct02411448","kind":"trial","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","route":"/trials/nct02411448/"},{"id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/"},{"id":"nct03033511","kind":"trial","name":"A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","route":"/trials/nct03033511/"},{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/"},{"id":"nct06754930","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","route":"/trials/nct06754930/"},{"id":"nct06430437","kind":"trial","name":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","route":"/trials/nct06430437/"},{"id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/"},{"id":"nct06589778","kind":"trial","name":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06589778/"},{"id":"nct07229729","kind":"trial","name":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07229729/"},{"id":"nct05949606","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05949606/"},{"id":"nct05956587","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other","route":"/trials/nct05956587/"},{"id":"nct05816252","kind":"trial","name":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-","route":"/trials/nct05816252/"},{"id":"nct06670196","kind":"trial","name":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan","route":"/trials/nct06670196/"},{"id":"nct06711900","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P","route":"/trials/nct06711900/"},{"id":"nct06448312","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06448312/"},{"id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/"},{"id":"nct05722015","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","route":"/trials/nct05722015/"},{"id":"nct06212752","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","route":"/trials/nct06212752/"},{"id":"nct05635708","kind":"trial","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","route":"/trials/nct05635708/"},{"id":"nct06644768","kind":"trial","name":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","route":"/trials/nct06644768/"},{"id":"nct07699328","kind":"trial","name":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07699328/"},{"id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/"},{"id":"nct07407933","kind":"trial","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07407933/"},{"id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07739758/"},{"id":"nct07169994","kind":"trial","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07169994/"},{"id":"nct07202364","kind":"trial","name":"A Study of YL202 in Patients With Advanced Solid Tumors","route":"/trials/nct07202364/"},{"id":"nct06568939","kind":"trial","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","route":"/trials/nct06568939/"},{"id":"nct06312137","kind":"trial","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","route":"/trials/nct06312137/"},{"id":"nct07325136","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","route":"/trials/nct07325136/"},{"id":"nct07680764","kind":"trial","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","route":"/trials/nct07680764/"},{"id":"nct06311721","kind":"trial","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","route":"/trials/nct06311721/"},{"id":"nct06687369","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L","route":"/trials/nct06687369/"},{"id":"nct06561386","kind":"trial","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N","route":"/trials/nct06561386/"},{"id":"nct06348199","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s","route":"/trials/nct06348199/"},{"id":"nct07005336","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr","route":"/trials/nct07005336/"},{"id":"nct04765059","kind":"trial","name":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04765059/"},{"id":"nct07564401","kind":"trial","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","route":"/trials/nct07564401/"},{"id":"nct07361497","kind":"trial","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","route":"/trials/nct07361497/"},{"id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","route":"/trials/nct07206498/"},{"id":"nct05318573","kind":"trial","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","route":"/trials/nct05318573/"},{"id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","route":"/trials/nct07541170/"},{"id":"nct06829459","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N","route":"/trials/nct06829459/"},{"id":"nct03178552","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct03178552/"},{"id":"nct05353257","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage","route":"/trials/nct05353257/"},{"id":"nct07361510","kind":"trial","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","route":"/trials/nct07361510/"},{"id":"nct07155174","kind":"trial","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","route":"/trials/nct07155174/"},{"id":"nct06780137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","route":"/trials/nct06780137/"},{"id":"nct07223047","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","route":"/trials/nct07223047/"},{"id":"nct06946797","kind":"trial","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","route":"/trials/nct06946797/"},{"id":"nct05801029","kind":"trial","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth","route":"/trials/nct05801029/"},{"id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/"},{"id":"nct07115043","kind":"trial","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","route":"/trials/nct07115043/"},{"id":"nct06606847","kind":"trial","name":"A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ","route":"/trials/nct06606847/"},{"id":"nct06417814","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","route":"/trials/nct06417814/"},{"id":"nct05048797","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N","route":"/trials/nct05048797/"},{"id":"nct05785767","kind":"trial","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","route":"/trials/nct05785767/"},{"id":"nct06452277","kind":"trial","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","route":"/trials/nct06452277/"},{"id":"nct04316364","kind":"trial","name":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","route":"/trials/nct04316364/"},{"id":"nct06512051","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06512051/"},{"id":"nct03390686","kind":"trial","name":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ","route":"/trials/nct03390686/"},{"id":"nct05557591","kind":"trial","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","route":"/trials/nct05557591/"},{"id":"nct05800015","kind":"trial","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","route":"/trials/nct05800015/"},{"id":"nct06161441","kind":"trial","name":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth","route":"/trials/nct06161441/"},{"id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/"},{"id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/"},{"id":"nct06041776","kind":"trial","name":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","route":"/trials/nct06041776/"},{"id":"nct07149363","kind":"trial","name":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","route":"/trials/nct07149363/"},{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/"},{"id":"nct05904379","kind":"trial","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","route":"/trials/nct05904379/"},{"id":"nct05840016","kind":"trial","name":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05840016/"},{"id":"nct05247684","kind":"trial","name":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","route":"/trials/nct05247684/"},{"id":"nct06943820","kind":"trial","name":"AK129 Combination Therapy for Advanced Solid Tumors","route":"/trials/nct06943820/"},{"id":"nct04687241","kind":"trial","name":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations","route":"/trials/nct04687241/"},{"id":"ample","kind":"trial","name":"AMPLE","route":"/trials/ample/"},{"id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/"},{"id":"nct06693336","kind":"trial","name":"An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer","route":"/trials/nct06693336/"},{"id":"nct07443397","kind":"trial","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","route":"/trials/nct07443397/"},{"id":"nct05841472","kind":"trial","name":"Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas","route":"/trials/nct05841472/"},{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","route":"/trials/nct01933932/"},{"id":"nct03974022","kind":"trial","name":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","route":"/trials/nct03974022/"},{"id":"astrum-005","kind":"trial","name":"ASTRUM-005","route":"/trials/astrum-005/"},{"id":"atlantis","kind":"trial","name":"ATLANTIS","route":"/trials/atlantis/"},{"id":"nct04923906","kind":"trial","name":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut","route":"/trials/nct04923906/"},{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/"},{"id":"nct07195695","kind":"trial","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","route":"/trials/nct07195695/"},{"id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/"},{"id":"nct07625644","kind":"trial","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","route":"/trials/nct07625644/"},{"id":"nct05317858","kind":"trial","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","route":"/trials/nct05317858/"},{"id":"nct04495153","kind":"trial","name":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","route":"/trials/nct04495153/"},{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","route":"/trials/capstone-1/"},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/"},{"id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/"},{"id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/"},{"id":"nct04379635","kind":"trial","name":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04379635/"},{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/"},{"id":"nct06300177","kind":"trial","name":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar","route":"/trials/nct06300177/"},{"id":"nct07472517","kind":"trial","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","route":"/trials/nct07472517/"},{"id":"nct07707895","kind":"trial","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct07707895/"},{"id":"nct05882058","kind":"trial","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct05882058/"},{"id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","route":"/trials/nct05555732/"},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/"},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/"},{"id":"nct06283719","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P","route":"/trials/nct06283719/"},{"id":"nct05431270","kind":"trial","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","route":"/trials/nct05431270/"},{"id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05751798/"},{"id":"nct06992609","kind":"trial","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","route":"/trials/nct06992609/"},{"id":"dutch-bone-metastasis-study","kind":"trial","name":"Dutch Bone Metastasis Study","route":"/trials/dutch-bone-metastasis-study/"},{"id":"nct07070440","kind":"trial","name":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","route":"/trials/nct07070440/"},{"id":"nct07473128","kind":"trial","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","route":"/trials/nct07473128/"},{"id":"nct06463665","kind":"trial","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","route":"/trials/nct06463665/"},{"id":"slotman-pci-es-sclc","kind":"trial","name":"EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer","route":"/trials/slotman-pci-es-sclc/"},{"id":"nct06956001","kind":"trial","name":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","route":"/trials/nct06956001/"},{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/"},{"id":"nct04083599","kind":"trial","name":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","route":"/trials/nct04083599/"},{"id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/"},{"id":"nct04619004","kind":"trial","name":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","route":"/trials/nct04619004/"},{"id":"nct07122687","kind":"trial","name":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small","route":"/trials/nct07122687/"},{"id":"ideate-lung02","kind":"trial","name":"IDeate-Lung02","route":"/trials/ideate-lung02/"},{"id":"nct05280470","kind":"trial","name":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05280470/"},{"id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07452224/"},{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/"},{"id":"nct06840704","kind":"trial","name":"Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer","route":"/trials/nct06840704/"},{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/"},{"id":"nct06030258","kind":"trial","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","route":"/trials/nct06030258/"},{"id":"nct05742607","kind":"trial","name":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","route":"/trials/nct05742607/"},{"id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06928389/"},{"id":"nct05490472","kind":"trial","name":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","route":"/trials/nct05490472/"},{"id":"jrosg-99-1","kind":"trial","name":"JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy","route":"/trials/jrosg-99-1/"},{"id":"nct06216301","kind":"trial","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","route":"/trials/nct06216301/"},{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/"},{"id":"nct06496048","kind":"trial","name":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","route":"/trials/nct06496048/"},{"id":"nct07153055","kind":"trial","name":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","route":"/trials/nct07153055/"},{"id":"nct06419179","kind":"trial","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","route":"/trials/nct06419179/"},{"id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","route":"/trials/nct06765109/"},{"id":"nct07306624","kind":"trial","name":"Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer","route":"/trials/nct07306624/"},{"id":"nct05116462","kind":"trial","name":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","route":"/trials/nct05116462/"},{"id":"nct05061550","kind":"trial","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","route":"/trials/nct05061550/"},{"id":"nct03916627","kind":"trial","name":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","route":"/trials/nct03916627/"},{"id":"nct07819591","kind":"trial","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","route":"/trials/nct07819591/"},{"id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/"},{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","route":"/trials/nct05224141/"},{"id":"nct04553133","kind":"trial","name":"PF-07104091 as a Single Agent and in Combination Therapy","route":"/trials/nct04553133/"},{"id":"nct03647163","kind":"trial","name":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","route":"/trials/nct03647163/"},{"id":"nct01064466","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","route":"/trials/nct01064466/"},{"id":"nct07145333","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","route":"/trials/nct07145333/"},{"id":"nct06430866","kind":"trial","name":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","route":"/trials/nct06430866/"},{"id":"nct04868877","kind":"trial","name":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina","route":"/trials/nct04868877/"},{"id":"nct05074810","kind":"trial","name":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","route":"/trials/nct05074810/"},{"id":"nct05256290","kind":"trial","name":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05256290/"},{"id":"nct03907852","kind":"trial","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","route":"/trials/nct03907852/"},{"id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","route":"/trials/nct05288205/"},{"id":"nct04787042","kind":"trial","name":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","route":"/trials/nct04787042/"},{"id":"nct06162572","kind":"trial","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06162572/"},{"id":"nct03944772","kind":"trial","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","route":"/trials/nct03944772/"},{"id":"nct05363280","kind":"trial","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","route":"/trials/nct05363280/"},{"id":"nct04613596","kind":"trial","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","route":"/trials/nct04613596/"},{"id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","route":"/trials/nct07154706/"},{"id":"nct07778316","kind":"trial","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","route":"/trials/nct07778316/"},{"id":"nct04152499","kind":"trial","name":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","route":"/trials/nct04152499/"},{"id":"nct05024214","kind":"trial","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","route":"/trials/nct05024214/"},{"id":"nct07175220","kind":"trial","name":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","route":"/trials/nct07175220/"},{"id":"nct05195632","kind":"trial","name":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung","route":"/trials/nct05195632/"},{"id":"nct07329322","kind":"trial","name":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto","route":"/trials/nct07329322/"},{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/"},{"id":"nct06396065","kind":"trial","name":"Phase III Study of AK112 for NSCLC Patients","route":"/trials/nct06396065/"},{"id":"nct07291037","kind":"trial","name":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti","route":"/trials/nct07291037/"},{"id":"nct07170995","kind":"trial","name":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva","route":"/trials/nct07170995/"},{"id":"nct06350097","kind":"trial","name":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L","route":"/trials/nct06350097/"},{"id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/"},{"id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","route":"/trials/nct04624204/"},{"id":"nct05358249","kind":"trial","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct05358249/"},{"id":"nct06616532","kind":"trial","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","route":"/trials/nct06616532/"},{"id":"pci-overview-1999","kind":"trial","name":"Prophylactic Cranial Irradiation Overview (Auperin meta-analysis)","route":"/trials/pci-overview-1999/"},{"id":"nct07636226","kind":"trial","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","route":"/trials/nct07636226/"},{"id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","route":"/trials/nct05703971/"},{"id":"nct03228667","kind":"trial","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","route":"/trials/nct03228667/"},{"id":"nct05144698","kind":"trial","name":"RAPA-201 Therapy of Solid Tumors","route":"/trials/nct05144698/"},{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/"},{"id":"nct06170788","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","route":"/trials/nct06170788/"},{"id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","route":"/trials/nct06074588/"},{"id":"nct06305754","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","route":"/trials/nct06305754/"},{"id":"nct06712355","kind":"trial","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","route":"/trials/nct06712355/"},{"id":"nct05117242","kind":"trial","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","route":"/trials/nct05117242/"},{"id":"nct04938817","kind":"trial","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","route":"/trials/nct04938817/"},{"id":"nct06841055","kind":"trial","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","route":"/trials/nct06841055/"},{"id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/"},{"id":"nct06712316","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","route":"/trials/nct06712316/"},{"id":"nct03970746","kind":"trial","name":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","route":"/trials/nct03970746/"},{"id":"nct04140526","kind":"trial","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","route":"/trials/nct04140526/"},{"id":"nct06449209","kind":"trial","name":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","route":"/trials/nct06449209/"},{"id":"nct05020457","kind":"trial","name":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","route":"/trials/nct05020457/"},{"id":"nct05351788","kind":"trial","name":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","route":"/trials/nct05351788/"},{"id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","route":"/trials/nct07296809/"},{"id":"nct07155200","kind":"trial","name":"Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)","route":"/trials/nct07155200/"},{"id":"nct07551635","kind":"trial","name":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC","route":"/trials/nct07551635/"},{"id":"nct07391813","kind":"trial","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","route":"/trials/nct07391813/"},{"id":"nct06457906","kind":"trial","name":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","route":"/trials/nct06457906/"},{"id":"nct04180371","kind":"trial","name":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","route":"/trials/nct04180371/"},{"id":"nct03061812","kind":"trial","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","route":"/trials/nct03061812/"},{"id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/"},{"id":"nct06117774","kind":"trial","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","route":"/trials/nct06117774/"},{"id":"nct06502977","kind":"trial","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","route":"/trials/nct06502977/"},{"id":"nct07016230","kind":"trial","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","route":"/trials/nct07016230/"},{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/"},{"id":"nct03836352","kind":"trial","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","route":"/trials/nct03836352/"},{"id":"nct06710132","kind":"trial","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","route":"/trials/nct06710132/"},{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/"},{"id":"nct05267626","kind":"trial","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","route":"/trials/nct05267626/"},{"id":"nct04745689","kind":"trial","name":"Study of AZD2811 + Durvalumab in ES-SCLC","route":"/trials/nct04745689/"},{"id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","route":"/trials/nct04644068/"},{"id":"nct06514027","kind":"trial","name":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","route":"/trials/nct06514027/"},{"id":"nct07030257","kind":"trial","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07030257/"},{"id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","route":"/trials/nct06881784/"},{"id":"nct05215340","kind":"trial","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","route":"/trials/nct05215340/"},{"id":"nct05651022","kind":"trial","name":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","route":"/trials/nct05651022/"},{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/"},{"id":"nct03775486","kind":"trial","name":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","route":"/trials/nct03775486/"},{"id":"nct06726148","kind":"trial","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","route":"/trials/nct06726148/"},{"id":"nct06726265","kind":"trial","name":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ","route":"/trials/nct06726265/"},{"id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/"},{"id":"nct07070518","kind":"trial","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","route":"/trials/nct07070518/"},{"id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","route":"/trials/nct04198766/"},{"id":"nct05403385","kind":"trial","name":"Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct05403385/"},{"id":"nct07100080","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy","route":"/trials/nct07100080/"},{"id":"nct05620134","kind":"trial","name":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct05620134/"},{"id":"nct06895031","kind":"trial","name":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct06895031/"},{"id":"nct06128837","kind":"trial","name":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","route":"/trials/nct06128837/"},{"id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","route":"/trials/nct04930432/"},{"id":"nct03476681","kind":"trial","name":"Study of NEO-201 in Solid Tumors Expansion Cohorts","route":"/trials/nct03476681/"},{"id":"nct05633667","kind":"trial","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","route":"/trials/nct05633667/"},{"id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","route":"/trials/nct07079475/"},{"id":"nct05546268","kind":"trial","name":"Study of Oral MRT-2359 in Selected Cancer Patients","route":"/trials/nct05546268/"},{"id":"nct04956692","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan","route":"/trials/nct04956692/"},{"id":"nct07777822","kind":"trial","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","route":"/trials/nct07777822/"},{"id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/"},{"id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/"},{"id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/"},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/"},{"id":"nct02674568","kind":"trial","name":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","route":"/trials/nct02674568/"},{"id":"nct03767348","kind":"trial","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","route":"/trials/nct03767348/"},{"id":"nct05089734","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05089734/"},{"id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct05186974/"},{"id":"nct06801834","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06801834/"},{"id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","route":"/trials/nct05098132/"},{"id":"nct05565417","kind":"trial","name":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05565417/"},{"id":"nct05887492","kind":"trial","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","route":"/trials/nct05887492/"},{"id":"nct06899126","kind":"trial","name":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","route":"/trials/nct06899126/"},{"id":"nct05578326","kind":"trial","name":"Study of Trilaciclib and Lurbinectidin","route":"/trials/nct05578326/"},{"id":"nct05978284","kind":"trial","name":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct05978284/"},{"id":"nct05925530","kind":"trial","name":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,","route":"/trials/nct05925530/"},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/"},{"id":"nct05546866","kind":"trial","name":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","route":"/trials/nct05546866/"},{"id":"nct07288177","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","route":"/trials/nct07288177/"},{"id":"nct05607550","kind":"trial","name":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With","route":"/trials/nct05607550/"},{"id":"nct07185997","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W","route":"/trials/nct07185997/"},{"id":"nct05676931","kind":"trial","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","route":"/trials/nct05676931/"},{"id":"nct05712902","kind":"trial","name":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","route":"/trials/nct05712902/"},{"id":"nct07489066","kind":"trial","name":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","route":"/trials/nct07489066/"},{"id":"nct07476287","kind":"trial","name":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed","route":"/trials/nct07476287/"},{"id":"nct07227298","kind":"trial","name":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","route":"/trials/nct07227298/"},{"id":"nct07472647","kind":"trial","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","route":"/trials/nct07472647/"},{"id":"nct04129502","kind":"trial","name":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct04129502/"},{"id":"takahashi-pci","kind":"trial","name":"Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer","route":"/trials/takahashi-pci/"},{"id":"nct04919811","kind":"trial","name":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","route":"/trials/nct04919811/"},{"id":"nct07583511","kind":"trial","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","route":"/trials/nct07583511/"},{"id":"nct04804644","kind":"trial","name":"Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of M","route":"/trials/nct04804644/"},{"id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct05955391/"},{"id":"nct06758401","kind":"trial","name":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu","route":"/trials/nct06758401/"},{"id":"time2","kind":"trial","name":"TIME2","route":"/trials/time2/"},{"id":"nct05468489","kind":"trial","name":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","route":"/trials/nct05468489/"},{"id":"nct05442060","kind":"trial","name":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N","route":"/trials/nct05442060/"},{"id":"nct07246863","kind":"trial","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07246863/"},{"id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07098988/"},{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","route":"/trials/nct06574347/"},{"id":"nct06343064","kind":"trial","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","route":"/trials/nct06343064/"},{"id":"nct03556228","kind":"trial","name":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","route":"/trials/nct03556228/"},{"id":"nct06448754","kind":"trial","name":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","route":"/trials/nct06448754/"},{"id":"nct06933329","kind":"trial","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06933329/"},{"id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct07038096/"}],"paper":[{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/"},{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/"},{"id":"paper-lee-clonal-history-small-cell-transformation-jco-2017","kind":"paper","name":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","route":"/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/"},{"id":"paper-george-sclc-genomic-profiles-nature-2015","kind":"paper","name":"Comprehensive genomic profiles of small cell lung cancer","route":"/key-papers/paper-george-sclc-genomic-profiles-nature-2015/"},{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/"},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"},{"id":"paper-doll-hill-smoking-lung-cancer-bmj-1950","kind":"paper","name":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer","route":"/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/"},{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/"},{"id":"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","kind":"paper","name":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","route":"/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/"},{"id":"paper-doll-peto-50-year-doctors-bmj-2004","kind":"paper","name":"Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back","route":"/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/"},{"id":"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","kind":"paper","name":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","route":"/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/"},{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/"},{"id":"paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016","kind":"paper","name":"Mutational signatures associated with tobacco smoking in human cancer","route":"/key-papers/paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016/"},{"id":"paper-nlst-nejm-2011","kind":"paper","name":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers","route":"/key-papers/paper-nlst-nejm-2011/"},{"id":"paper-gay-sclc-subtypes-inflamed-cancer-cell-2021","kind":"paper","name":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","route":"/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/"},{"id":"paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999","kind":"paper","name":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","route":"/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/"},{"id":"paper-baine-sclc-subtype-immunohistochemistry-jto-2020","kind":"paper","name":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","route":"/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/"},{"id":"paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000","kind":"paper","name":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","route":"/key-papers/paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000/"},{"id":"paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013","kind":"paper","name":"Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis","route":"/key-papers/paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013/"},{"id":"paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999","kind":"paper","name":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","route":"/key-papers/paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999/"}],"journal":[{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","route":"/journals/clinical-lung-cancer/"},{"id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/"},{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","route":"/journals/thoracic-cancer/"},{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","route":"/journals/chinese-journal-of-lung-cancer/"}],"drug":[{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/"},{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/"},{"id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/"},{"id":"alisertib","kind":"drug","name":"Alisertib","route":"/drugs/alisertib/"},{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/"},{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/"},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"au-007","kind":"drug","name":"AU-007","route":"/drugs/au-007/"},{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/"},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/"},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/"},{"id":"or502","kind":"drug","name":"OR502","route":"/drugs/or502/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/"},{"id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"},{"id":"regn7075","kind":"drug","name":"REGN7075","route":"/drugs/regn7075/"},{"id":"roginolisib","kind":"drug","name":"Roginolisib","route":"/drugs/roginolisib/"},{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"},{"id":"socazolimab","kind":"drug","name":"Socazolimab","route":"/drugs/socazolimab/"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"},{"id":"tng260","kind":"drug","name":"TNG260","route":"/drugs/tng260/"},{"id":"tno155","kind":"drug","name":"TNO155","route":"/drugs/tno155/"},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"},{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/"},{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"},{"id":"vistusertib","kind":"drug","name":"Vistusertib","route":"/drugs/vistusertib/"},{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"}],"idea":[{"id":"idea-bio1-cfrna-plasticity-tracking","kind":"idea","name":"Detect tumours changing cell type from RNA in the blood","route":"/ideas/idea-bio1-cfrna-plasticity-tracking/"},{"id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/"},{"id":"idea-bio1-ctc-derived-explants","kind":"idea","name":"Grow models from tumour cells in the blood when a biopsy is impossible","route":"/ideas/idea-bio1-ctc-derived-explants/"},{"id":"idea-lung-brain-metastasis-prevention-as-a-primary-endpoint","kind":"idea","name":"Measure brain metastasis prevention as a primary endpoint, not as a secondary one","route":"/ideas/idea-lung-brain-metastasis-prevention-as-a-primary-endpoint/"},{"id":"idea-mri-surveillance-replaces-pci","kind":"idea","name":"MRI surveillance replaces prophylactic cranial irradiation in SCLC","route":"/ideas/idea-mri-surveillance-replaces-pci/"},{"id":"idea-bio1-omomyc-mrna","kind":"idea","name":"mRNA-delivered MYC decoy proteins instead of MYC inhibitors","route":"/ideas/idea-bio1-omomyc-mrna/"},{"id":"idea-lung-uk-screening-testing-and-access-gaps","kind":"idea","name":"Publish the four numbers the NHS lung cancer pathway does not currently measure: reflex testing rate, genomic turnaround, surgical access and a lung-specific waiting time in every nation","route":"/ideas/idea-lung-uk-screening-testing-and-access-gaps/"},{"id":"idea-lung-small-cell-platform-with-shared-controls-and-subtypes","kind":"idea","name":"Run small-cell lung cancer as one platform with shared controls and subtype stratification","route":"/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/"},{"id":"idea-bio1-translation-dependency-myc","kind":"idea","name":"Starve MYC-driven tumours by blocking protein production machinery","route":"/ideas/idea-bio1-translation-dependency-myc/"},{"id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/"},{"id":"idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery","kind":"idea","name":"Treat the deprivation gradient in lung cancer as a defect in delivery that can be fixed and measured","route":"/ideas/idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery/"}],"pairing":[{"id":"tigit-plus-pd1-caution","kind":"pairing","name":"Caution: TIGIT + PD-(L)1 blockade","route":"/pairings/tigit-plus-pd1-caution/"},{"id":"chemo-io-then-maintenance-sclc","kind":"pairing","name":"Chemo-immunotherapy induction → maintenance intensification (SCLC)","route":"/pairings/chemo-io-then-maintenance-sclc/"},{"id":"radiation-plus-io","kind":"pairing","name":"Radiotherapy + immunotherapy","route":"/pairings/radiation-plus-io/"},{"id":"tarlatamab-vs-idxd-sequence","kind":"pairing","name":"Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC","route":"/pairings/tarlatamab-vs-idxd-sequence/"}],"roadmap":[{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/"}],"person":[{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","route":"/people/alexis-cortot/"},{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/"},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/"},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/"},{"id":"caroline-dive","kind":"person","name":"Caroline Dive","route":"/people/caroline-dive/"},{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","route":"/people/charles-rudin/"},{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/"},{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/"},{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/"},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/"},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/"},{"id":"karen-kelly","kind":"person","name":"Karen Kelly","route":"/people/karen-kelly/"},{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/"},{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/"},{"id":"martin-schuler","kind":"person","name":"Martin Schuler","route":"/people/martin-schuler/"},{"id":"michael-boyer","kind":"person","name":"Michael Boyer","route":"/people/michael-boyer/"},{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","route":"/people/nobuyuki-yamamoto/"},{"id":"roman-thomas","kind":"person","name":"Roman Thomas","route":"/people/roman-thomas/"},{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","route":"/people/scott-antonia/"},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/"},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/"},{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","route":"/people/suresh-ramalingam/"},{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/"},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/"}],"bottleneck":[{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/"}],"collection":[{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/"}]}}